
Mantle Cell Lymphoma
Latest Content
Latest Videos
More News

In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.

The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.

Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.

An independent review of BTK inhibitors in mantle cell lymphoma finds areas are of strength both second-generation therapies, as authors call for clinical trials to inform guidelines.

China survey reveals what R/R mantle cell lymphoma patients and doctors value after BTK failure—overall survival tops trade-offs despite CRS risk.

There are significant, and uneven, knowledge gaps among physicians treating patients with mantle cell lymphoma and chronic lymphocytic leukemia across countries and settings, a survey finds.

After CAR T-cell therapy relapse in mantle cell lymphoma, an antibody drug conjugate regimen adapted from DLBCL shows durable remission.

Matched real-world MCL data shows acalabrutinib and zanubrutinib lower atrial fibrillation vs ibrutinib, with fewer bleeding events.

Low-dose CAR T drives durable responses in mantle cell lymphoma, DLBCL and multiple myeloma when CD27⁻CD39⁻ effector cells meet a key threshold.

DLBCL and MCL patients spotlight fatigue, pain, and emotional burden while backing PRO surveys to shape quality-of-life trial endpoints.

Case series suggests glofitamab bridges relapsed mantle cell lymphoma to CAR T, with strong responses and mostly low-grade CRS.

EBMT updates mantle cell lymphoma guidance: TP53-based risk stratification drives BTK inhibitor use and CAR T therapy (Tecartus, Breyanzi), reshaping transplant timing.

Chemo-free zanubrutinib plus rituximab in phase 3 MANGROVE cuts progression/death risk 43% vs BR for frontline mantle cell lymphoma.

As SYMPATICO publishes final data for ibrutinib–venetoclax relapsed mantle cell lymphoma, a new commentary discusses how combinations with zanubrutinib and sonrotoclax-era could take over.

SEER and Medicare data project rising DLBCL and MCL cases through 2032, intensifying payer strain and demand for Brukinsa, Calquence, and CAR-T access.

Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center details evolving mantle cell lymphoma care: ECHO acalabrutinib-BR and chemo-free zanubrutinib BOVen triplets challenge standards.

The bispecific T-cell engager could fulfill an unmet need among patients with mantle cell lymphoma who progress after treatment with a BTK inhibitor.

Analyses to be presented at ASCO show zanubrutinib offers improved survival benefits and longer time to the next treatment over another BTK inhibitor in 2 common indications.

The next-generation BCL2 inhibitor is approved for adults with relapsed or refractory MCL who have received at least 2 lines of systemic treatment

The complexity of MCL calls for personalized therapeutic strategies, but prior authorization protocols may not recognize distinct patient needs.

Real-world data show zanubrutinib cuts atrial fibrillation, major bleeding, and mortality versus ibrutinib in B‑cell cancers—guiding safer BTK inhibitor choices.

Mosunetuzumab, a bispecific, plus polatuzumab vedotin, an antibody-drug conjugate, deliver high response rates in relapsed MCL, potentially enabling outpatient community oncology treatment and wider patient access.

A new study suggests that incorporating proteomic data can help refine risk stratification in mantle cell lymphoma (MCL).

Adults can undergo CAR T-cell therapy for relapsed or refractory mantle cell lymphoma after the full approval of the treatment.

Dual inhibition of BIRC5 and MCL-1 showed strong synergistic activity in preclinical models of MCL.





